New psychoactive substances market seen hitting $35.4B by 2033

By AI, Created 9:50 AM UTC, May 20, 2026, /AGP/ – Persistence Market Research says the global new psychoactive substances market will grow from $22.5 billion in 2026 to $35.4 billion by 2033, led by demand for neurological, psychiatric and cancer-related therapies. The report points to North America’s current lead, Asia Pacific’s faster growth and rising use of digital health, e-commerce and regulated distribution.

Why it matters: - The market’s growth reflects rising demand for therapies that can better address neuropathic pain, mental health disorders and cancer-related palliative care. - The report also points to broader use of controlled therapeutic pathways and digital health tools, which could expand access in both hospitals and decentralized care settings. - The shift matters because the category sits at the intersection of treatment innovation, regulation and patient safety.

What happened: - Persistence Market Research projected the global new psychoactive substances market at $22.5 billion in 2026. - The firm forecast the market will reach $35.4 billion by 2033. - The report said the market will grow at a 4.8% compound annual growth rate during the forecast period. - The analysis was released May 4, 2026, from London. - A free sample report is available online.

The details: - Neuropathic pain, mental health disorders and oncology-related palliative care are the main demand drivers in the forecast. - The report said healthcare providers are looking for alternatives to traditional opioids as chronic and neuropathic pain burdens rise. - Growing clinical interest in cannabinoid-based and stimulant-like compounds is broadening therapeutic options. - Digital patient monitoring and real-world evidence collection are improving treatment tracking and adoption, according to the report. - E-commerce-supported distribution systems and standardized regulatory frameworks are improving supply chain efficiency and patient access. - North America is expected to hold about 42% of the market in 2026. - Asia Pacific is expected to be the fastest-growing region. - Europe remains a mature market with strong regulatory oversight. - Stimulants are projected to hold the largest product share at about 33% in 2026. - Synthetic opioids are expected to grow fastest among product types. - Neuropathic disorders are expected to account for about 41% of the market in 2026. - Cancer-related palliative care is expected to be the fastest-growing indication. - Retail pharmacies, hospital pharmacies and e-commerce are the main distribution channels in the study.

Between the lines: - The report frames the category as a clinical innovation story, not just a specialty-drug market. - Strong growth in synthetic opioids and cannabinoid-related compounds suggests demand is shifting toward targeted symptom management and safer analgesic options. - The market is highly fragmented, with major pharmaceutical companies and emerging biotech firms competing on neuropsychiatric and pain-management pipelines. - Companies are investing in AI-driven drug discovery, novel molecular design and advanced clinical trial frameworks. - Strategic collaborations and regulatory partnerships appear to be becoming more important for market entry. - Recent developments include tighter scrutiny of precursor chemicals used in synthetic drug manufacturing. - Ongoing clinical trials involving psilocybin, cannabidiol derivatives and other psychoactive compounds could change the competitive landscape. - The report also highlighted custom insights and customization for buyers seeking deeper market data.

What’s next: - Persistence Market Research expects growth to continue as digital health, personalized medicine and controlled distribution frameworks expand. - Regulatory and safety challenges remain a constraint, even as therapeutic applications broaden. - The report said continued innovation in neurological and psychiatric care should keep long-term demand rising across global healthcare systems.

The bottom line: - New psychoactive substances are moving deeper into regulated clinical use, and market growth is being driven by unmet need in pain, psychiatry and oncology.